Predicting the Toxicity of Weekly Docetaxel in Advanced Cancer
- 43 Downloads
To determine the safety profile of 40 mg/m2 docetaxel administered weekly to a mixed population of advanced cancer patients and identify predictors of toxicity and survival following treatment with weekly docetaxel in this population.
Patients and methods
68 patients with advanced cancer were enrolled into the study. Various patient characteristics, including inflammatory and nutritional status, docetaxel pharmacokinetics and liver function were investigated. Predictors of treatment-related toxicity and survival were analysed using multivariate logistic regression and Cox proportional hazards analysis, respectively.
27 patients (40%) experienced grade 3 or 4 toxicity, mainly gastrointestinal toxicities (20%), leukopenia (16%) and neutropenia (12%), during the first 8 weeks of docetaxel treatment. Docetaxel pharmacokinetics were the only predictive factor for haematological toxicity. The odds of severe haematological toxicity were approximately 9-fold higher for patients with reduced docetaxel clearance (e.g. <30 L/h). The odds of non-haematological toxicity were about 3-fold higher for patients with elevated levels of inflammatory markers: α1-acid glycoprotein (AAGP) >1.5 g/L or C-reactive protein >10 mg/L). Multivariate analysis indicated that weight loss, liver dysfunction and elevated levels of AAGP were independently significant predictors of survival.
This is the first description of factors predictive of the toxicity and survival following weekly administration of docetaxel. Patients with reduced clearance of docetaxel and elevated markers of inflammation experienced worse adverse effects, while patients with weight loss, liver dysfunction and elevated markers of inflammation had worse survival.
- 1.Bruno R, Vivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinetic Biopharm 1996 Apr; 24(2): 153–72Google Scholar
- 12.Gusmao AB, Bines J, Martins RG, et al. Primary chemotherapy with weekly docetaxel (Taxotere) in poor prognosis advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 42bGoogle Scholar
- 13.Gervais R, Ducolone AMD, Breton J-L, et al. Mult-centre, randomised, Phase II trial of docetaxel (Taxotere) 75mg.m2 q3w versus 40mg/m2 weekly in patients with pretreated nonsmall cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 310aGoogle Scholar
- 14.Sedky L, Saad El-Dine I, Hashem B, et al. Weekly docetaxel vs every 3-week in advanced breast cancer: results of a pilot comparative study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 50bGoogle Scholar
- 40.Zulian GB, Gold G, Herrmann F, et al. Mini nutritional assessment and cancer. Nestle Nutr Workshop Ser Clin Perform Programme 1999; 1: 93-8, 99–100Google Scholar